Fate Therapeutics, Inc.
FATEDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How FATE's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ProTmune | Phase 2 | Hematologic Malignancies | - | - |
Lupus Nephritis
1 drug in this indication
treatment-resistant autoimmune disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Fate Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fate Therapeutics, Inc.'s (FATE) pipeline across Phase 2. Its lead program is ProTmune (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fate Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Fate Therapeutics, Inc. (FATE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FATE biotech catalysts?→
Add FATE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fate Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.